A group of anticoagulant and / or anticomplement peptides and their applications
By designing and optimizing the Kunitz peptide group, especially Rona13 and its mutants, the problem of simultaneously inhibiting blood clotting and complement systems was solved, achieving highly efficient anticoagulation and anticomplement effects and reducing disease risk.
Patent Information
- Application Number
- CN202310605954.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-05-26
AI Technical Summary
Existing technologies are unable to effectively inhibit both blood clotting and the complement system simultaneously, leading to immune and inflammatory diseases. Furthermore, the development of complement inhibitors from natural products faces issues of efficiency and toxicity.
A group of Kunitz peptides, including Hyta11, Hydi12, Hydi21 and Rona13, was designed. By optimizing the amino acid sequence and disulfide bond linkage, their anticoagulation and anticomplement functions were enhanced. Mutants were screened to obtain peptides with higher anticoagulation and anticomplement activities, such as Rona13-4 and Rona13-5.
It achieves simultaneous inhibition of intrinsic and extrinsic coagulation pathways, significantly prolongs APTT time, enhances the inhibitory effect on FXIa and complement, and reduces bleeding risk and inflammatory response.
Smart Images

Figure CN116444650B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically, it relates to a group of anticoagulant and / or anticomplement polypeptides and their applications. Background Technology
[0002] Kunitz peptides are an important class of serine protease inhibitors that are ubiquitous in various animals. The first Kunitz-type serine protease inhibitor, bovine trypsin inhibitor (BPTI), was discovered by Krau and Kunitzt. Its molecule contains three pairs of disulfide bonds formed in a 1–6, 2–4, 3–5 configuration. One pair of disulfide bonds is located on the molecule's surface, while the other two pairs are located inside the molecule. The entire molecule is pear-shaped, composed of two antiparallel β-sheets, two α-helices, a β-turn, and several rings. Kunitz-type serine protease inhibitors have five main active sites: P1, P1′, P3, P3′, and P4, all located on a solvent-exposed ring. The P1 site is the key active site for inhibition, and the specificity of the inhibitor is determined by the properties of the amino acid residues at the P1 site [1]. The size of the side chain of the amino acid residues at the P1′ site has a great influence on the binding constant of the inhibitory enzyme. Substitution with larger side chain residues will lead to a decrease in the binding constant [2]. Substitution of residues at the P4 site often produces negative effects, which will lead to a great change in the conformation of the active region loop, thereby affecting the binding of the enzyme and the inhibitor [3]. Kunitz-type serine protease inhibitors participate extensively in host blood coagulation, fibrinolysis, inflammation and ion channel blockade by regulating the activity of target serine proteases. They are the most studied serine protease inhibitors and have complex and diverse biological functions.
[0003] In order to live in their host, parasites must fight against the host's blood defense system, including the blood coagulation system and the complement system. To date, many Kunitz peptides with anticoagulant functions have been isolated from ectoparasites and endoparasites. Anticoagulant substances in ectoparasites such as ticks are mainly found in salivary glands, saliva, eggs, and lymphocytes [4]. They can be divided into four types: Kunitz-type protease inhibitors, Kazal-type protease inhibitors, cysteine-rich trypsin inhibitors, and serine protease inhibitors. Anticoagulant substances found in endoparasites include Ascaris-type and Kunitz-type anticoagulant components. The most widely studied is the Kunitz-type serine protease inhibitor, whose main function is to exert an anticoagulant effect, which is beneficial for the parasite to take up host blood [4]. The complement system is widely involved in the body's biological defense function and immune regulation effects. Overactivation of the complement system leads to a variety of immune and inflammatory diseases, including ischemia-reperfusion injury, sepsis, and autoimmune diseases. Therefore, the complement system is an important target for the development of drugs for immune and inflammatory diseases. In recent years, the research and development of novel complement inhibitors with high efficiency and low toxicity derived from natural products has begun to attract widespread attention from scholars at home and abroad. Anticomplement active molecules have been discovered from Polygonum cuspidatum, Houttuynia cordata, ticks, and Schistosoma japonicum, and natural products have become a new direction for the research and development of complement system drugs.
[0004] We previously screened the Kunitz peptide TSM1 (patent number ZL201810463151.9) from tapeworms, which possesses dual anticoagulant and anticomplement activities. TSM1 is a Kunitz-type serine protease inhibitor composed of 63 amino acids. The molecule contains six cysteine residues linked by three pairs of disulfide bonds at C8–C58, C17–C54, and C33–C41. The C17–C54 disulfide bond is located on the molecule's surface, while the other two pairs are located internally. The most prominent structural feature of TSM1 is two antiparallel β-sheets, one end connected to the C17–C54 disulfide bond, and the other end connected to a β-turn. The N-terminal and C-terminal residues each form an α-helix.
[0005] Based on this, the present invention is proposed.
[0006] References
[0007] 1.Krowarsch D,Otlewski J:Amino-acid substitutions at the fullyexposed P1 site of bovine pancreatic trypsin inhibitor affect itsstability.Protein Sci 2001,10(4):715-724.
[0008] 2.Grzesiak A, Krokoszynska I, Krowarsch D, Buczek O, Dadlez M, Otlewski J: Inhibition of six serine proteinases of the human coagulation system bymutants of bovine pancreatic trypsin inhibitor.The Journal of biologicalchemistry 2000,275(43):33346-33352.
[0009] 3.Grzesiak A, Buczek O, Petry I, Szewczuk Z, Otlewski J: Inhibition of serine proteinases from human blood clotting system by squash inhibitormutants. Biochim Biophys Acta 2000, 1478(2): 318-324.
[0010] 4. Li Haijian, Zhao Rixia: Expression and activity identification of NaKuI10, a plasmin inhibitor of hookworm. Chinese Journal of Pathogenic Biology, 2018, 13(7):724-728. Summary of the Invention
[0011] This invention first relates to a group of polypeptides for anticoagulation and / or anticomplement, said polypeptide group being;
[0012] The sequence of the Hyta11 polypeptide is shown in SEQ ID NO.1:
[0013] KMSYINRCNLPISSGRCRGYFLRYGYDSETDECRPFVYSGCRGNRNNFFTYNECMNRCFMRFK
[0014] The Hydi12 polypeptide, sequence of which is shown in SEQ ID NO.2:
[0015] WGSMSLINRCFMPIDSGKCRGYFIRYGYDSETDKCIPFVYGGCRGNRNNFFTNEQCMQRCYMKFK
[0016] The Hydi21 polypeptide, sequence of which is shown in SEQ ID NO.3:
[0017] WGSMSLINRCFMPIDSGKCRGYFIRFGYDSETDKCIPFVYGGCRGNRNNFFTNEQCMQRCYMKFK
[0018] Rona13 polypeptide, sequence shown in SEQ ID NO.4:
[0019] SMSLINRCFMPIDSGKCRGYFIRYGYDSETDDCYPFIYGGCRGNRNNFFTYEECMQRCYLKFK.
[0020] The present invention also relates to a nucleotide fragment encoding the polypeptide group, preferably, the nucleotide fragment is cDNA, the sequence of which is as follows:
[0021] The cDNA sequence of the Hyta11 polypeptide is shown in SEQ ID NO.5:
[0022] Aaaatgagctatattaaccgctgcaacctgccgattagcagcggccgctgccgcggctattttctgcgctatggctatgatagcgaaaccgatgaatgccgcc cgtttgtgtatagcggctgccgcggcaaccgcaacaacttttttacctataacgaatgcatgaaccgctgctttatgcgctttaaatga
[0023] The cDNA sequence of the Hydi12 polypeptide is shown in SEQ ID NO.6:
[0024] Tggggcagcatgagcctgattaaccgctgctttatgccgattgatagcggcaaatgccgcggctattttattcgctatggctatgatagcgaaaccgataaatgc attccgtttgtgtatggcggctgccgcggcaaccgcaacaacttttttaccaacgaacagtgcatgcagcgctgctatatgaaatttaaatga
[0025] The cDNA sequence of the Hydi21 polypeptide is shown in SEQ ID NO.7:
[0026] Tggggcagcatgagcctgattaaccgctgctttatgccgattgatagcggcaaatgccgcggctattttattcgctttggctatgatagcgaaaccgataaatgc attccgtttgtgtatggcggctgccgcggcaaccgcaacaacttttttaccaacgaacagtgcatgcagcgctgctatatgaaatttaaatga
[0027] The Rona13 polypeptide cDNA sequence is shown in SEQ ID NO.8:
[0028] Agcatgagcctgattaaccgctgctttatgccgattgatagcggcaaatgccgcggctattttattcgctatggctatgatagcgaaaccgatgattgctatccgt ttatttatggcggctgccgcggcaaccgcaacaacttttttacctatgaagaatgcatgcagcgctgctatctgaaatttaaatga.
[0029] This invention also relates to the use of the aforementioned polypeptide group or its coding sequence in the preparation of anticoagulant drugs.
[0030] Preferably, the anticoagulant is an anticoagulant that inhibits the intrinsic coagulation pathway, which refers to prolonging the activated partial thromboplastin time (APTT).
[0031] This invention also relates to the application of the Rona13 polypeptide in the preparation of anticoagulant drugs. The anticoagulant drugs refer to drugs that simultaneously inhibit both intrinsic and extrinsic coagulation pathways.
[0032] This invention also relates to the use of the aforementioned polypeptide group or its coding sequence in the preparation of anticomplement drugs.
[0033] This invention also relates to a mutant of the Rona13 polypeptide for anticoagulation and / or anticomplement, wherein the mutant is,
[0034] Rona13-4, its amino acid sequence and cDNA sequence are shown in SEQ ID NO.9 and SEQ ID NO.10, respectively;
[0035] Rona13-5, its amino acid sequence and cDNA sequence are shown in SEQ ID NO.11 and SEQ ID NO.12, respectively;
[0036] This invention also relates to the following applications of mutants of the Rona13 polypeptide or its coding sequence.
[0037] (1) Preparation of anticoagulant drugs; preferably, the anticoagulant drugs are drugs that simultaneously inhibit intrinsic coagulation pathway and extrinsic coagulation pathway;
[0038] (2) Preparation of anticomplement drugs.
[0039] The beneficial effects of this invention are as follows:
[0040] (1) Four novel Kunitz peptide groups were obtained and their anticoagulant and / or anticomplement functions were evaluated, demonstrating their potential for the preparation of anticoagulant and anticomplement drugs;
[0041] (2) The present invention further screened and studied mutants of the peptide to obtain mutants with higher anticoagulation and anticomplement activities. Attached Figure Description
[0042] Figure 1 , Four SDS-PAGE electrophoresis of Kunitz peptides. The lanes in the figure are as follows: 1 is protein marker, 2 is TSM1, 3 is Hyta11, 4 is Hydi12, 5 is Hydi21, and 6 is Rona13.
[0043] Figure 2 , Four The anticoagulant function of the Kunitz peptide was evaluated. The X-axis represents the final concentration of the peptide, and the Y-axis represents the ratio of APTT, PT, and TT times between the peptide group and the negative control group (PBS group).
[0044] Figure 3 , FourEvaluation of the anticoagulant function of the Kunitz peptide: 3A, 3B, and 3C are the concentration-dependent curves of APTT, PT, and TT of Rona13, respectively. The X-axis represents different concentrations of the peptide, with the final concentration gradients of the peptide being 0, 0.0875 μM, 0.175 μM, 0.35 μM, 0.7 μM, 1.4 μM, and 2.8 μM. The Y-axis represents the ratio of APTT, PT, and TT times between the peptide group and the negative control group (PBS group).
[0045] Figure 4 The coagulation factor inhibitory activity of peptide Rona13 is shown. For models 4A, 4B, 4C, 4D, 4E, and 4F, the X-axis represents different concentrations of Rona13, and the Y-axis represents the residual enzyme activity of serine proteases.
[0046] Figure 5 Enzyme kinetics of Rona13 against FXIa
[0047] Figure 5A is a double reciprocal plot of the rate of inhibition of FXIa by the anticoagulant peptide Rona13 against different concentrations of substrate S2765, with the X-axis representing the reciprocal of the substrate concentrations at 400 μM, 500 μM, 600 μM, 800 μM, and 1200 μM; the Y-axis represents the reciprocal of the inhibition rate of FXIa by the final concentrations of Rona13 at 0, 0.019 μM, and 0.078 μM; the equation Rona13(0) is: y = 13.465x + 19.037, R 2 =0.9771; the equation Rona13 (0.019μM) is: y = 44.053x + 37.824, R 2 =0.9778; the equation Rona13 (0.078μM) is: y = 111.03x + 114.09, R 2 =0.8178;
[0048] 5B shows a plot of three concentrations of the peptide against Km / Vmax, with the equation: y = 1.2244x + 16.326, Rm 2 =0.9953;
[0049] 5C is plotted against 1 / Vmax for three concentrations of the peptide, with the equation: y = 1.2363x + 16.741, R 2 =0.997.
[0050] Figure 6 , Four Evaluation of the anticomplement function of Kunitz peptides: The X-axis represents different peptides at a final concentration of 10 μM. The Y-axis represents the inhibition rate of complement by the peptides. The negative control was GVB buffer, and the positive control was ultrapure water.
[0051] Figure 7Thromboelastography of peptide Rona13
[0052] Curves 7A, a, b, and c represent the thromboelastography curves for the groups with Rona13 concentrations of 0 (saline group), 5 μM group, and 10 μM group, respectively.
[0053] 7B. The X-axis represents the thromboelastography parameter values, where R is the clotting time, K is the clot formation rate, Angle is the angle between the tangent and the horizontal line, and MA is the clot strength. The Y-axis represents the ratio of the thromboelastography parameter values of the polypeptide group to those of the saline group.
[0054] Figure 8 Design of eight analog molecules of Rona13.
[0055] Figure 9 Identification of 8 analogues of the peptide Rona13
[0056] Figure A: 1 is the protein marker, 2 is Rona13, 3 is Rona13-1, 4 is Rona13-2, 5 is Rona13-3, and 6 is Rona13-4;
[0057] Figure B: 1 is the protein marker, 2 is Rona13, 3 is Rona13-5, 4 is Rona13-6, 5 is Rona13-7, and 6 is Rona13-8.
[0058] Figure 10 Evaluation of the anticoagulant function of eight analogues of the peptide Rona13
[0059] A, B, and C represent the APTT, PT, and TT measurements of the peptide, respectively. The X-axis represents the final concentration of the peptide. The Y-axis represents the ratio of APTT, PT, and TT times between the peptide group and the negative control group (PBS group).
[0060] Figure 11 Evaluation of the anticomplement function of eight analogues of the peptide Rona13
[0061] The X-axis represents different peptides at a final concentration of 10 μM, and the Y-axis represents the inhibition rate of complement by the peptides. The negative control is GVB buffer, and the positive control is ultrapure water. Detailed Implementation
[0062] Example 1: Discovery and Recombinant Expression of Four Novel Anticoagulant Peptides
[0063] Analogs of the peptide TSM1 from parasitic tapeworms were screened by sequence alignment. Analysis of these sequences revealed the complete Kunitz sequence, yielding the amino acid sequences of four peptides as follows:
[0064] Hyta11, sequence as shown in SEQ ID NO.1:
[0065] KMSYINRCNLPISSGRCRGYFLRYGYDSETDECRPFVYSGCRGNRNNFFTYNECMNRCFMRFK
[0066] Hydi12, sequence as shown in SEQ ID NO.2:
[0067] WGSMSLINRCFMPIDSGKCRGYFIRYGYDSETDKCIPFVYGGCRGNRNNFFTNEQCMQRCYMKFK
[0068] Hydi21, sequence as shown in SEQ ID NO.3:
[0069] WGSMSLINRCFMPIDSGKCRGYFIRFGYDSETDKCIPFVYGGCRGNRNNFFTNEQCMQRCYMKFK
[0070] Rona13, sequence as shown in SEQ ID NO.4:
[0071] SMSLINRCFMPIDSGKCRGYFIRYGYDSETDDCYPFIYGGCRGNRNNFFTYEECMQRCYLKFK
[0072] The cDNA sequence after codon optimization is as follows:
[0073] The Hyta11 cDNA sequence is shown in SEQ ID NO.5:
[0074] Aaaatgagctatattaaccgctgcaacctgccgattagcagcggccgctgccgcggctattttctgcgctatggctatgatagcgaaaccgatgaatgccgcccgtttgtgtatagcggctgccgcggcaaccgcaacaacttttttacctataacgaatgcatgaaccgctgctttatgcgctttaaatga
[0075] The Hydi12 cDNA sequence is shown in SEQ ID NO.6:
[0076] Tggggcagcatgagcctgattaaccgctgctttatgccgattgatagcggcaaatgccgcggctattttattcgctatggctatgatagcgaaaccgataaatgcattccgtttgtgtatggcggctgccgcggcaaccgcaacaacttttttaccaacgaacagtgcatgcagcgctgctatatgaaatttaaatga
[0077] Hydi21, the cDNA sequence is shown in SEQ ID NO.7:
[0078] Tggggcagcatgagcctgattaaccgctgctttatgccgattgatagcggcaaatgccgcggctattttattcgctttggctatgatagcgaaaccgataaatgcattccgtttgtgtatggcggctgccgcggcaaccgcaacaacttttttaccaacgaacagtgcatgcagcgctgctatatgaaatttaaatga
[0079] Rona13, the cDNA sequence is shown in SEQ ID NO.8:
[0080] Agcatgagcctgattaaccgctgctttatgccgattgatagcggcaaatgccgcggctattttattcgctatggctatgatagcgaaaccgatgattgctatccgtttatttatggcggctgccgcggcaaccgcaacaacttttttacctatgaagaatgcatgcagcgctgctatctgaaatttaaatga
[0081] Recombinant plasmids containing the target sequence cDNA were prepared and transformed into DE3 to obtain expression bacteria, using a similar method to that used for TSM1 peptide (see: ZL201810463151.9 for details). Generally, successfully transformed bacterial cultures were activated in 3% Kana LB liquid medium, expanded, and then induced with IPTG (final concentration 1 mM) for another 4 hours. The induced bacterial culture was centrifuged, the supernatant discarded, and the precipitate resuspended in ice-cold PBS. After sonication to disrupt the cell wall, the supernatant was discarded, the precipitate was washed twice with ice-cold PBST, centrifuged again, and resuspended in 0.03 g / mL reduced glutathione denaturing buffer for 2 hours at room temperature. The supernatant after high-speed centrifugation was slowly renatured at 16°C in renaturing buffer containing 0.012 g / mL oxidized glutathione. The renaturing buffer was concentrated and desalted using ultrafiltration, purified by RP-HPLC, and the purified protein was freeze-dried into a powder, then quantified using BCA and dispensed.
[0082] SDS-PAGE electrophoresis images of the four purified Kunitz peptides are shown below. Figure 1 .
[0083] Example 2: Study on the anticoagulant function of polypeptide groups
[0084] (I) APTT function detection of peptides:
[0085] 1. Turn on the TSA9000C coagulation analyzer and preheat an appropriate amount of APTT reagent and Cacl2 reagent;
[0086] 2. Add 25 μL of different concentrations of peptide, negative control (ddH2O) and positive control (final concentration of heparin is 2.14 μg / mL) to a 1 mL EP tube in sequence, and 50 μL of healthy human plasma. Incubate at room temperature for 15 minutes. During incubation, enter the sample information and APTT test items.
[0087] 3. Place the EP tube into the sample position on the instrument. During the detection, the instrument will automatically add 50 μL of APTT reagent and 50 μL of Cacl2 reagent.
[0088] 4. Import the data into an Excel spreadsheet and use the graphing software Prism to create a graph.
[0089] The results are as follows Figure 2 As shown in A, specifically...
[0090] When the final peptide concentration was 2.8 μM, both TSM1 (Yangshen) and the screened peptide group showed inhibitory effects on the intrinsic coagulation pathway.
[0091] The extension factor of TSM1 for APTT time is 2.000 ± 0.008.
[0092] Hyta11 extended APTT time by 2.114 ± 0.033.
[0093] Hydi12 extended APTT time by 3.956 ± 0.057.
[0094] The extension factor of APTT time by Hydi21 was 3.912 ± 0.078.
[0095] Rona13 extended APTT time by 6.29 ± 0.032;
[0096] also, Rona13 has a weak inhibitory effect on extrinsic coagulation pathways, with a PT time prolongation factor of 1.415 ± 1.415. 0.004 Figure 2 B); TSM1 and the other three peptides had no inhibitory effect on the common coagulation pathway. Figure 2 C) .
[0097] (II) PT function detection of peptides:
[0098] 1. Turn on the TSA9000C coagulation analyzer and preheat an appropriate amount of PT reagent;
[0099] 2. Add 25 μL of different concentrations of peptide, negative control (ddH2O) and positive control (final concentration of heparin is 2.14 μg / mL) to a 1 mL EP tube in sequence, and 50 μL of healthy human plasma. Incubate at room temperature for 15 minutes. During incubation, enter the sample information and PT detection items.
[0100] 3. Place the EP tube into the sample position on the instrument. During the detection, the instrument will automatically add 100 μL of APTT reagent.
[0101] 4. Import the data into an Excel spreadsheet and use the graphing software Prism to create a graph.
[0102] (III) TT function detection of peptides:
[0103] 1. Turn on the TSA9000C coagulation analyzer and preheat an appropriate amount of TT reagent;
[0104] 2. Add 25 μL of different concentrations of peptide, negative control (ddH2O) and positive control (final concentration of heparin is 2.14 μg / mL) to a 1 mL EP tube in sequence, and 100 μL of healthy human plasma. Incubate at room temperature for 15 minutes. During incubation, enter the sample information and PT detection items.
[0105] 3. Place the EP tube into the sample position on the instrument. During the detection, the instrument will automatically add 100 μL of APTT reagent.
[0106] 4. Import the data into an Excel spreadsheet and use the graphing software Prism to create a graph.
[0107] As the APTT results showed, Rona13, a peptide with enhanced anticoagulant activity, was present in the polypeptide group. Subsequently, the concentration-dependent effects of APTT, PT, and TT on Rona13 were analyzed. It was found that Rona13 prolongation in a concentration-dependent manner with increasing peptide concentration. Regarding APTT and PT times, specifically, Rona13 extended the APTT time by 2 times at a concentration of 0.57 μM. However, it did not extend the TT time.effect( Figure 3 ) .
[0108] (iv) Coagulation factor testing:
[0109] Six serine proteases—Plasmin, Kallikrein, FXIIa, FXa, FXIa, and FIIa—were selected for protease inhibitory activity assays. The specific experimental methods are as follows.
[0110] 1. Dilute the recombinant peptide to concentrations of 10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM, and 0 μM using coagulation factor buffer. Then, dilute XIa and the corresponding substrates to concentrations of 1 μg / mL and 1200 μM, respectively, using buffer.
[0111] 2. Add 25 μl of enzyme and 25 μl of peptides of different concentrations to the wells of a 96-well plate, and add 70 μl of substrate to the other well. Place the plate on a shaker and incubate at 37°C for 15 min. Place the plate in the wells of a microplate reader and use a multipipe to add 50 μl of substrate to the enzyme-peptide mixing well. Detect at 405 nm every 1 min for a total of 7 times.
[0112] 3. Repeat the experiment three times, import the data into an Excel spreadsheet to plot the inhibition curve, and calculate IC50.
[0113] The results show ( Figure 4 ),
[0114] (1) When the final concentration of Rona13 was 2.5 μM, it had a significant inhibitory effect on Plasmin, Kalikrein and FXIa; the IC50 values were 0.058±0.010 μM, 0.156±0.009 μM and 0.113±0.010 μM, respectively, according to statistical regression.
[0115] (2) Rona13 showed weak inhibitory effect on FXa, with an IC50 value of 1.343±0.277μM;
[0116] (3) Rona13 has no significant inhibitory effect on FXIIa and FIIa.
[0117] In summary, the inhibitory effect of Rona13 on Plasmin in the fibrinolytic system indicates that Rona13 reduces the risk of bleeding after inhibiting FXIa and Kallikrein in the coagulation contact system.
[0118] (V) Enzyme kinetics experiment:
[0119] 1. Select three appropriate peptide concentrations, dilute the coagulation factor to 1 μg / mL, and then dilute the FXIa substrate to 1200 μM, 600 μM, 400 μM, 300 μM, 240 μM, and 200 μM with buffer.
[0120] 2. In a 96-well plate, add 25 μl of enzyme and 25 μl of peptide to each well in one vertical row. In another vertical row, add the substrate to each well in descending order of concentration. For the remaining two peptide concentrations, repeat the process as described above, only changing the peptide concentration while keeping other conditions unchanged.
[0121] 3. Place the 96-well plate on a shaker and incubate at 37°C for 15 minutes. Place the plate in the wells of the microplate reader and use a multi-particle pipette to add 50 μl of substrate to the corresponding enzyme-peptide mixing well. Detect at a wavelength of 405 nm. Detect once every 1 minute for a total of 7 times.
[0122] To investigate the inhibitory type of Rona13 on FXIa, enzyme kinetics experiments were conducted. Based on the IC50 values in the coagulation factor inhibition curves, an appropriate peptide concentration was set. The IC50 value of Rona13 inhibiting FXIa differed significantly from the experimental FXIa concentration. Therefore, a double reciprocal plot of 1 / V versus 1 / [S] was used to determine the inhibitory type of Rona13 on FXIa. At a concentration of 0 μM, the X-axis intercept of the double reciprocal plot of the anticoagulant peptide Rona13 was -1 / Km, yielding a Km value of 707.306 μM. Figure 5 The X-intercept -Ki was obtained by plotting Km / Vmax against different concentrations of Rona13, and the Ki value was found to be 13.333 × 10⁻³ μM. Figure 5 By plotting Rona13 at different concentrations using 1 / Vmax, the X-axis intercept -Ki′ was obtained, and the value of Ki′ was found to be 13.541×10⁻³ μM.
[0123] Since Ki≈Ki′, therefore, Rona13 inhibits FXIa through non-competitive inhibition (a type of mixed inhibition). (Special form) indicates that the polypeptide does not bind to the FXIa active site, but binds to sites outside the active site. .
[0124] Example 3: Study on the anticoagulation mechanism of peptide Rona13
[0125] To investigate whether the peptide Rona13 has an anticoagulant effect in human whole blood, we used a thromboelastography instrument to detect the effect of Rona13 on whole blood coagulation. With the saline group as the control, the peptide was set at concentrations of 0 (saline group), 5 μM group and 10 μM group, and each concentration was repeated twice.
[0126] Thromboelastography results ( Figure 7 The results showed that Rona13 at concentrations of 5 μM and 10 μM inhibited blood clotting in human whole blood, and the inhibitory effect was concentration-dependent.
[0127] The inhibitory effect of Rona13 on whole blood coagulation was evaluated using four parameters of thromboelasticity.
[0128] In the 5μM group: the R value increased by 1.567±0.009, the K value increased by 1.392±0.083, the Angle value decreased by 0.833±0.038, and the MA value decreased by 0.856±0.021.
[0129] In the 10μM group: the R value increased by 2.051±0.000, the K value increased by 1.862±0.138, the Angle value decreased by 0.686±0.053, and the MA value decreased by 0.842±0.013.
[0130] In summary, the increase in clotting time (R) indicates that the inhibitory effect of peptides on clotting factors is continuously enhanced with the increase in peptide concentration. The increase in clot formation rate (K) and the decrease in the angle between the horizontal line and the tangent of blood clotting time (Angle) indicate that fibrin formation is reduced with the increase in peptide concentration. The decrease in MA value indicates that the strength of the formed clot is reduced, indicating that the number of platelets involved in the clotting process is reduced. The changes in these four parameters reflect the concentration-dependent inhibition of Rona13 in human whole blood. Blood clotting .
[0131] Example 4: Study on the anti-complement function of the polypeptide group
[0132] In this embodiment, rabbit anti-sheep serum is used as a hemolysin to sensitize sheep red blood cells. Sensitized sheep red blood cells can activate the classical complement pathway under the conditions of Ca2+ and Mg2+, thereby causing hemolysis of sheep red blood cells. The degree of hemolysis is directly proportional to the complement content.
[0133] (a) Determination of complement potency:
[0134] 1. Collect serum (NHS) from 10 healthy volunteers as complement, mix well, aliquot, and store at -80℃.
[0135] 2. Mix 500 μL of sheep red blood cell suspension with 1 mL of ice-cold GVB buffer, centrifuge at 4°C and 1000 rpm for 10 minutes, discard the supernatant, and wash three times; take 20 μL of red blood cell pellet and add it to 980 μL of ice-cold GVB buffer to prepare 2% sheep red blood cells.
[0136] 3. Preparation of sensitized sheep red blood cells (EA): Rabbit anti-sheep serum was diluted with GVB buffer to a ratio of 1:1000 as a hemolysin, and then incubated with an equal volume of 2% sheep red blood cells (SRBC) at 37°C for 30 minutes to complete the sensitization of SRBC.
[0137] 4. Complement (NHS) was diluted with GVB at ratios of 1:5, 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, and 1:640. The components were added according to the proportions in Table 1. The solutions were incubated in a 37°C water bath for 30 minutes, then centrifuged at 5000 rpm for 10 minutes at 4°C. 200 μL of the supernatant from each tube was transferred to a 96-well plate, and the absorbance was measured at 405 nm. The absorbance of the ultrapure water-soluble blood vessel was used as the standard for complete hemolysis, and the hemolysis rate was calculated.
[0138] Table 1. Volumes (μL) of each component added for complement potency determination
[0139]
[0140] Plot the complement dilution factor on the X-axis and the hemolysis rate caused by complement at each dilution factor on the Y-axis. Select the lowest complement concentration that can cause near-total lysis of sensitized sheep red blood cells (in this experiment, it was a 1:20 dilution of serum) as the critical complement concentration required to ensure the system.
[0141] (II) Determination of anticomplement activity of peptides via the classical pathway:
[0142] 1. Take the critical concentration of NHS and 10 μM peptide in equal volume and mix well. Incubate at 37°C for 10 minutes. Add EA and GVB according to Table 2. Incubate at 37°C for 30 minutes. Centrifuge at 4°C and 5000 rpm for 10 minutes. Take 200 μL of supernatant from each tube into a 96-well plate and measure the absorbance at 405 nm.
[0143] 2. Plot a graph with the peptide as the X-axis and the hemolysis inhibition rate as the Y-axis. The experiment also included complement, total lysis, and GVB groups.
[0144] Table 2. Volumes (μL) of each component added in the classic route anticomplement hemolysis test
[0145]
[0146] Complement inhibition rate of the peptide = (A405 complement group - A405 peptide group) / (A405 complement group - A405 GVB group) × 100%
[0147] 3. Take critical concentration NHS and mix it with equal volumes of 0μM, 2.5μM, 5μM, 7.5μM, 10μM, 15μM, and 20μM peptides. Incubate at 37℃ for 10 minutes. Add EA and GVB, incubate at 37℃ for 30 minutes, and then centrifuge at 4℃ and 5000rpm for 10 minutes. Take 200μL of the supernatant from each tube into a 96-well plate and measure the absorbance at 405nm.
[0148] 4. Plot a graph with the peptide as the X-axis and the hemolysis inhibition rate as the Y-axis. The experiment also included complement, total lysis, and GVB groups.
[0149] 5. Mix equal volumes of 1:20NHS, 1:30NHS, and 1:40NHS with 10μM peptide, incubate at 37℃ for 10 minutes, add EA and GVB, incubate at 37℃ for 30 minutes, centrifuge at 4℃ and 5000rpm for 10 minutes, take 200μL of supernatant from each tube into a 96-well plate, and measure the absorbance at 405nm.
[0150] The peptide was plotted on the X-axis and the hemolysis inhibition rate on the Y-axis. The experiment included complement, total lysis, and GVB groups.
[0151] The results are as follows Figure 6 As shown, the anti-complement activity of Hyta11, Hydi12, and Hydi21 was improved compared with TSM1, with complement inhibition rates of 97.24%, 97.41%, and 87.95%, respectively.
[0152] Next, the inhibitory effects of different concentrations of peptides on complement were detected. The results showed that all peptides inhibited complement activity in a concentration-dependent manner.
[0153] The IC50 values of peptides Hyta11, Hydi12, and Hydi21 for inhibiting complement were 5.190 ± 0.291 μM, 3.478 ± 0.288 μM, and 5.375 ± 1.622 μM, respectively.
[0154] Example 5: Expression and purification of the Rona13 mutant
[0155] Eight mutants were designed by performing point mutations, combined mutations, and chimeric mutations on Rona13. Figure 11 Specifically,
[0156] Rona13-2 was designed by mutating the I37 site to V37 using point mutation.
[0157] Rona13-6 was designed by mutating the amino acids at the R18 and G19 sites to A18 and L19 sites, respectively, using a combined mutation approach.
[0158] Using a chimeric mutation approach, amino acids at the P1, P1', and P2' sites of the non-anticoagulant Kunitz peptide were chimericly inserted into Rona13 to design Rona13-7 and Rona13-8.
[0159] Rona13-1 was designed by inserting the amino acid sequence of the Kunitz peptide Hydi12, which has strong anti-complement activity, into the Rona13 sequence.
[0160] The amino acid sequence of the Kunitz peptide shp4, which has strong anticoagulant activity, was inserted into the Rona13 sequence to design Rona13-4 and Rona13-5.
[0161] The Rona13 mutant protein expression mode is the same as that of wild-type Rona13. Expression was induced using a heterologous *E. coli* expression system, and eight mutants (Rona13-1, Rona13-2, Rona13-3, Rona13-4, Rona13-5, Rona13-6, Rona13-7, and Rona13-8) were successfully prepared. BCA quantification and SDS-PAGE gel electrophoresis were performed. Figure 9 ).
[0162] Example 6: Screening for the anticoagulant function of the Rona13 mutant
[0163] Following the method in Example 2, the anticoagulant function of the mutant was screened and tested, and the results were as follows ( Figure 10 )show,
[0164] (1) Rona13-4 enhances the effect of prolonging APTT time.
[0165] (2) Rona13-6, Rona13-7, and Rona13-8 have virtually no effect on prolonging APTT time.
[0166] The results indicate that the R18 and G19 sites are key sites for Rona13 to exert its anticoagulant activity. The enhanced anticoagulant activity of Rona13-4 suggests that the amino acids at the intercalation sites enhance the anticoagulant activity of Rona13. Based on this, an anticoagulant activity-enhancing peptide, Rona13-4, was obtained.
[0167] Rona13-4, amino acid sequence as shown in SEQ ID NO.9:
[0168] SEQ ID NO.9:
[0169] SMSLINRCFMPIDEGICRGYFRRYGYDSETDDCYPFIYGGCRGNRNNFFTYEECMQRCYLKFK
[0170] The cDNA sequence corresponding to the optimized codons is as follows.
[0171] The cDNA sequence of Rona13-4 is shown in SEQ ID NO.11:
[0172] SEQ ID NO.11:
[0173] Agcatgagcctgattaaccgctgctttatgccgattgatgaaggcatttgccgcggctattttcgccgctatggctatgatagcgaaaccgatgattgctatccgtttatttatggcggctgccgcggcaaccgcaacaacttttttacctatgaagaatgcatgcagcgctgctatctgaaatttaaatga.
[0174] Example 7: Screening for anti-complement function of Rona13 mutants
[0175] Following the method in Example 4, the anti-complement function of the mutants was screened, and it was found that Rona13-5 exhibited enhanced anti-complement activity. The anti-complement activity of Rona13-1, Rona13-2, Rona13-7, and Rona13-8 was significantly decreased. Figure 11 ).
[0176] Based on this, an anticomplement activity-enhancing peptide, Rona13-5, was obtained.
[0177] The amino acid sequence of Rona13-5 is shown in SEQ ID NO.10:
[0178] SEQ ID NO.10:
[0179] SMSLINRCFMPIDEGICRGYFRRYGYDSETDDCYPFYYGGCLGNRNNFFTYEECMQRCYLKFK
[0180] The cDNA sequence corresponding to the optimized codons is as follows.
[0181] The cDNA sequence of Rona13-5 is shown in SEQ ID NO.12:
[0182] SEQ ID NO.12:
[0183] Agcatgagcctgattaaccgctgctttatgccgattgatgaaggcatttgccgcggctattttcgccgctatggctatgatagcgaaaccgatgattgctatccgttttattatggcggctgcctgggcaaccgcaacaacttttttacctatgaagaatgcatgcagcgctgctatctgaaatttaaatga.
[0184] Finally, it should be noted that the above embodiments are only used to help those skilled in the art understand the essence of the present invention, and are not intended to limit the scope of protection of the present invention.
Claims
1. A group of polypeptides for anticoagulation, wherein the polypeptide is Rona13-4, and its amino acid sequence is shown in SEQ ID NO.
9.
2. A nucleotide fragment encoding the polypeptide of claim 1.
3. The nucleotide fragment according to claim 2, characterized in that, The nucleotide fragment is cDNA, and its sequence is shown in SEQ ID NO.
11.
4. The use of the polypeptide of claim 1 or the nucleotide fragment of claim 2 or 3 in the preparation of anticoagulant drugs.
5. The application according to claim 4, characterized in that, The anticoagulant drug mentioned above refers to a drug that simultaneously inhibits the intrinsic coagulation pathway and the extrinsic coagulation pathway; the intrinsic coagulation pathway refers to prolonging the activated partial thromboplastin time (APTT).
Citation Information
Patent Citations
TSM1 peptide and its application in the preparation of anticomplement drugs
CN108586605B
TSM1 polypeptide and application of same in preparation of anticomplement drugs
CN108586605A
Kunitz type plasma kallikrein inhibitors
US5780265A
